Compare INDV & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDV | ADPT |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2014 | 2019 |
| Metric | INDV | ADPT |
|---|---|---|
| Price | $35.53 | $25.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $49.00 | $28.31 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8100.00 | 63.89 |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $1,239,000,000.00 | $276,976,000.00 |
| Revenue This Year | $7.50 | $5.94 |
| Revenue Next Year | $5.07 | $22.42 |
| P/E Ratio | $21.23 | ★ N/A |
| Revenue Growth | 4.29 | ★ 54.77 |
| 52 Week Low | $23.55 | $12.00 |
| 52 Week High | $42.81 | $30.74 |
| Indicator | INDV | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 44.89 |
| Support Level | $33.45 | $23.73 |
| Resistance Level | $35.54 | $26.51 |
| Average True Range (ATR) | 0.96 | 1.43 |
| MACD | 0.10 | -0.37 |
| Stochastic Oscillator | 38.21 | 12.46 |
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.